NanoViricides (NYSE:NNVC – Get Free Report) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Friday.
NanoViricides Stock Up 0.3 %
Shares of NanoViricides stock opened at $1.50 on Friday. NanoViricides has a 12-month low of $1.00 and a 12-month high of $3.59. The stock has a market capitalization of $20.86 million, a P/E ratio of -2.14 and a beta of 0.94. The company has a 50-day simple moving average of $1.61 and a 200 day simple moving average of $1.79.
NanoViricides (NYSE:NNVC – Get Free Report) last posted its quarterly earnings data on Friday, September 27th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.01.
Institutional Trading of NanoViricides
About NanoViricides
NanoViricides, Inc, a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases.
Featured Stories
- Five stocks we like better than NanoViricides
- How to Calculate Stock Profit
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- High Dividend REITs: Are They an Ideal Way to Diversify?
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- What Are Dividend Achievers? An Introduction
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for NanoViricides Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoViricides and related companies with MarketBeat.com's FREE daily email newsletter.